$SCNI News

Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing

Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement

Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement

Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?

Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Scinai Files Prospectus For Resale Of Up To 2,706,450 ADS By YA II PN

Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Immunotherapeutics shares are trading higher after the company announced a $2.61 million private placement financing.

Scinai Immunotherapeutics shares are trading higher after the company announced a $2.61 million private placement financing.

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics Enters Securities Purchase Agreement For Up To 5.21M ADS And Warrants Priced At $0.48 Per Unit

Scinai Immunotherapeutics Completes Strategic Corporate Reorganization Establishing CDMO Platform Alongside Streamlined R&D Organization